Galectin Therapeutics Inc (GALT)
2.78
+0.06
(+2.21%)
USD |
NASDAQ |
Nov 22, 16:00
2.77
-0.01
(-0.36%)
After-Hours: 20:00
Galectin Therapeutics Free Cash Flow: -33.68M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -33.68M |
| June 30, 2024 | -32.78M |
| March 31, 2024 | -34.28M |
| December 31, 2023 | -32.96M |
| September 30, 2023 | -35.50M |
| June 30, 2023 | -36.21M |
| March 31, 2023 | -33.81M |
| December 31, 2022 | -31.06M |
| September 30, 2022 | -30.77M |
| June 30, 2022 | -27.42M |
| March 31, 2022 | -25.97M |
| December 31, 2021 | -24.31M |
| September 30, 2021 | -22.77M |
| June 30, 2021 | -25.98M |
| March 31, 2021 | -22.61M |
| December 31, 2020 | -20.60M |
| September 30, 2020 | -18.95M |
| June 30, 2020 | -12.21M |
| March 31, 2020 | -11.94M |
| December 31, 2019 | -10.85M |
| September 30, 2019 | -9.096M |
| June 30, 2019 | -9.198M |
| March 31, 2019 | -9.947M |
| December 31, 2018 | -10.18M |
| September 30, 2018 | -12.08M |
| Date | Value |
|---|---|
| June 30, 2018 | -13.62M |
| March 31, 2018 | -15.54M |
| December 31, 2017 | -15.89M |
| September 30, 2017 | -16.85M |
| June 30, 2017 | -17.17M |
| March 31, 2017 | -16.78M |
| December 31, 2016 | -16.41M |
| September 30, 2016 | -16.14M |
| June 30, 2016 | -17.78M |
| March 31, 2016 | -16.16M |
| December 31, 2015 | -16.98M |
| September 30, 2015 | -15.50M |
| June 30, 2015 | -13.69M |
| March 31, 2015 | -13.12M |
| December 31, 2014 | -12.43M |
| September 30, 2014 | -10.96M |
| June 30, 2014 | -9.16M |
| March 31, 2014 | -8.68M |
| December 31, 2013 | -7.484M |
| September 30, 2013 | -7.589M |
| June 30, 2013 | -8.185M |
| March 31, 2013 | -8.437M |
| December 31, 2012 | -7.505M |
| September 30, 2012 | -7.293M |
| June 30, 2012 | -6.468M |
Free Cash Flow Range, Past 5 Years
-36.21M
Minimum
Jun 2023
-10.85M
Maximum
Dec 2019
-26.23M
Average
-26.70M
Median
Free Cash Flow Benchmarks
| Microbot Medical Inc | -8.97M |
| Alaunos Therapeutics Inc | -11.76M |
| SELLAS Life Sciences Group Inc | -33.07M |
| Oragenics Inc | -7.682M |
| Anavex Life Sciences Corp | -30.00M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -8.538M |
| Cash from Financing (Quarterly) | 10.00M |
| Free Cash Flow Per Share (Quarterly) | -0.1371 |
| Free Cash Flow Yield | -19.51% |